Santiment data ranks DeFiChain as the most actively developed yield farming project over the past 30 days with a development activity score of 64.63, more than Santiment data ranks DeFiChain as the most actively developed yield farming project over the past 30 days with a development activity score of 64.63, more than

DeFiChain Leads All Yield Farming Projects in GitHub Activity Over the Past 30 Days

2026/03/03 07:32
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Santiment data ranks DeFiChain as the most actively developed yield farming project over the past 30 days with a development activity score of 64.63, more than 50% higher than second-placed Aave at 40.33.

The Top Five

DeFiChain’s 64.63 development activity score sits in a different category from everything else on the list. Aave at 40.33 is the closest competitor and the gap between first and second is larger than the gap between second and tenth. For a project trading at $0.001094 with a market cap of just $906,970, the development intensity is disproportionate to its current market footprint.

Whether that development activity is building toward something that closes the valuation gap or simply reflects a dedicated but small team working on an underfollowed project is a question the GitHub commits alone can’t answer.

Aave at rank 65 globally with a $1.85 billion market cap is the most established name in the top five. Its 40.33 development score is consistent with a mature protocol that continues shipping updates rather than a team in early build mode. The 2.68% daily price gain at $120.94 reflects a project that has been quietly holding value better than most DeFi blue chips during the February correction.

Yearn.Finance rounds out the top three at 19.73 development activity, trading at $2,750.76 with a $98.2 million market cap. The price per token is high but the market cap tells the real story about its current scale. Beefy Finance at 5.17 and Gearbox Protocol at 3.13 complete the top five, both showing minor price movements in opposite directions over the past 24 hours.

What Development Activity Actually Measures

The Santiment development activity metric tracks meaningful GitHub commits and code changes rather than raw commit counts, which makes it harder to game through trivial pushes. A project scoring 64 on this metric over 30 days is producing a consistent, substantial volume of real code output.

That distinction matters because development activity and price are weakly correlated in the short term but more meaningfully correlated over longer periods. Projects that stop building eventually stop having users. Projects that keep building at high intensity through bear markets tend to emerge with more functional products on the other side.

The current environment, where most crypto assets are down significantly from cycle highs and retail attention has rotated elsewhere, is exactly when development activity data becomes more informative. It identifies which teams are still working regardless of price action.

Cardano Stablecoin Supply Jumps as Stablecoin-to-TVL Ratio Surpasses 33%

The Rest of the List

Inverse Finance at 2.37 development activity score is down 0.56% on the day. YieldBasis at 0.633 is up 3.49%, the strongest daily performer in the bottom half of the list. Quickswap matches YieldBasis at 0.633 with a 0.73% daily gain. DeFi Yield Protocol at 0.6 is down 2.98% with a $31,230 market cap, the smallest in the dataset by a considerable margin.

SushiSwap rounds out the top ten at 0.533 development activity, trading at $0.210 with a $60.26 million market cap. Its presence in the list at rank 425 globally reflects a protocol that has lost significant ground from prior cycle highs but continues active development across its Ethereum-based lending and DEX infrastructure.

The post DeFiChain Leads All Yield Farming Projects in GitHub Activity Over the Past 30 Days appeared first on ETHNews.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09